USA flag logo/image

An Official Website of the United States Government

VITRIFICATION OF GENETICALLY-ENGINEERED ISLETS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54456
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43DK060280-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ORGAN RECOVERY SYSTEMS, INC.
ORGAN RECOVERY SYSTEMS, INC. 701 E BAY ST, SUITE 433 CHARLESTON, SC 29403-0500
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: VITRIFICATION OF GENETICALLY-ENGINEERED ISLETS
Agency: HHS
Contract: N/A
Award Amount: $111,280.00
 

Abstract:

Transplantation of pancreatic islets for the treatment of diabetes mellitus is widely anticipated to eventually provide a cure once a means for preventing rejection is found without reliance upon global immunosuppression. Long-term storage of islets is crucial for the organization of transplantation, islet banking, tissue matching, organ sharing, immuno-manipulation and multiple donor transplantation. Existing methods of cryopreservation involving freezing are known to be suboptimal providing only about 50% survival. The development of techniques for ice-free cryopreservation of mammalian tissues using both natural and synthetic ice blocking molecules, and the process of vitrification (formation of a glass as opposed to crystalline ice) has been a focus of research for Organ Recovery Systems during recent years. These approaches have established in other tissues that vitrification can markedly improve survival by circumventing ice-induced injury. The aim of this Phase I study is to apply these new technologies to the long- term storage of pancreatic islets. The study is designed to optimize both the pre-vitrification hypothermic shipping conditions using newly developed media and to compare new proprietary techniques for ice- free cryopreservation with conventional freezing protocols. Optimized techniques will then be applied to genetically-modified islets designed to overcome immune responses in the diabetic host in Phase II. PROPOSED COMMERCIAL APPLICATIONS: The ultimate aim of this project is to develop a marketable package comprising cryopreserved genetically-modified islets that can be removed from vitrified storage, rewarmed simply without specialist training or equipment, and transplanted to produce a well tolerated graft with biological effectiveness that exceeds that of insulin injection therapy.

Principal Investigator:

Michael J. Taylor

Business Contact:


8437226756
Small Business Information at Submission:

ORGAN RECOVERY SYSTEMS, INC.
2570 E DEVON AVE DES PLAINES, IL 60018

EIN/Tax ID: 364356620
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No